Open Access

Regulation of P450 oxidoreductase by gonadotropins in rat ovary and its effect on estrogen production

  • Yoshihiko Inaoka1,
  • Takashi Yazawa1,
  • Tetsuya Mizutani1,
  • Koichi Kokame2,
  • Kenji Kangawa2,
  • Miki Uesaka1,
  • Akihiro Umezawa3 and
  • Kaoru Miyamoto1Email author
Reproductive Biology and Endocrinology20086:62

https://doi.org/10.1186/1477-7827-6-62

Received: 06 October 2008

Accepted: 16 December 2008

Published: 16 December 2008

Abstract

Background

P450 oxidoreductase (POR) catalyzes electron transfer to microsomal P450 enzymes. Its deficiency causes Antley-Bixler syndrome (ABS), and about half the patients with ABS have ambiguous genitalia and/or impaired steroidogenesis. POR mRNA expression is up-regulated when mesenchymal stem cells (MSCs) differentiate into steroidogenic cells, suggesting that the regulation of POR gene expression is important for steroidogenesis. In this context we examined the regulation of POR expression in ovarian granulosa cells by gonadotropins, and its possible role in steroidogenesis.

Methods

Changes in gene expression in MSCs during differentiation into steroidogenic cells were examined by DNA microarray analysis. Changes in mRNA and protein expression of POR in the rat ovary or in granulosa cells induced by gonadotropin treatment were examined by reverse transcription-polymerase chain reaction and western blotting. Effects of transient expression of wild-type or mutant (R457H or V492E) POR proteins on the production of estrone in COS-7 cells were examined in vitro. Effects of POR knockdown were also examined in estrogen producing cell-line, KGN cells.

Results

POR mRNA was induced in MSCs following transduction with the SF-1 retrovirus, and was further increased by cAMP treatment. Expression of POR mRNA, as well as Cyp19 mRNA, in the rat ovary were induced by equine chorionic gonadotropin and human chorionic gonadotropin. POR mRNA and protein were also induced by follicle stimulating hormone in primary cultured rat granulosa cells, and the induction pattern was similar to that for aromatase. Transient expression of POR in COS-7 cells, which expressed a constant amount of aromatase protein, greatly increased the rate of conversion of androstenedione to estrone, in a dose-dependent manner. The expression of mutant POR proteins (R457H or V492E), such as those found in ABS patients, had much less effect on aromatase activity than expression of wild-type POR proteins. Knockdown of endogenous POR protein in KGN human granulosa cells led to reduced estrone production, indicating that endogenous POR affected aromatase activity.

Conclusion

We demonstrated that the expression of POR, together with that of aromatase, was regulated by gonadotropins, and that its induction could up-regulate aromatase activity in the ovary, resulting in a coordinated increase in estrogen production.

Background

The ovary is one of the major steroidogenic organs, and ovarian follicular development is initiated by follicle stimulating hormone (FSH) secreted by the pituitary gland. FSH-induced follicular development involves granulosa cell proliferation and differentiation [1, 2]. FSH induces steroidogenic enzymes in ovarian granulosa cells leading to the production of steroid hormones, including estrogens. P450 aromatase (CYP19) is one of the steroidogenic enzymes regulated by FSH, and catalyzes the biosynthesis of estrogens from C19 steroids in the granulosa cells [3].

P450 oxidoreductase (POR) is an 82-kDa membrane-bound flavoprotein [4, 5] responsible for the transfer of electrons from nicotine adenine dinucleotide phosphate to flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), and finally to microsomal P450 enzymes, including aromatase, as well as to several non-P450 enzymes [6, 7]. Several clinical studies have reported that mutations in POR are sufficient to cause Antley-Bixler syndrome (ABS), which is characterized by skeletal malformations. In some cases, ABS patients have genital ambiguity, and in some of the cases female ABS patients present with polycystic ovary syndrome [6, 811]. The clinical features are primarily explained by the impaired activities of CYP21A2, CYP17A1, and CYP19 involved in steroidogenesis [11, 12].

Bone marrow-derived mesenchymal stem cells (MSCs) are defined as pluripotent cells, and have been shown to differentiate into adipocytes, chondrocytes, osteoblasts, and hematopoietic-supporting stroma, both in vivo and ex vivo [1315]. We recently reported that stable transfection of MSCs with the transcription factor, steroidogenic factor-1 (SF-1), followed by treatment with cAMP, led to their conversion into steroidogenic cells [16]. These cells offer a possible clinical source of stem cells for the treatment of diseases of steroidogenic organs, and represent a powerful tool for studying the differentiation of the steroidogenic lineage.

In this study, we investigated the changes in gene expression in MSCs during differentiation into steroidogenic cells. POR gene expression, as well as that of various steroidogenic enzymes, was induced by SF-1 and cAMP. It was also induced by gonadotropins in rat ovary and granulosa cells. We also examined the effects of wild-type and mutant POR expression on aromatase activity, and the effects of knockdown of endogenous POR in mammalian cell lines. Our results suggest that up-regulation of POR expression by gonadotropins, as well as that of aromatase, could enhance ovarian estrogen synthesis.

Methods

Diethylstilbestrol (DES), 8-bromoadenosine 3'-5'-cyclic monophosphate (8-Br-cAMP), and gentamicin were purchased from Sigma (St. Louis, MO). Ovine FSH was obtained from the National Institutes of Health (NIH). Equine chorionic gonadotropin (eCG) was purchased from Teikokuzouki, Inc. (Tokyo, Japan). Human chorionic gonadotropin (hCG) was obtained from Sankyo (Tokyo, Japan). Ex Taq DNA polymerase, Escherichia coli DNA ligase, and DNA ligation kit were purchased from Takara Biomedicals (Kyoto, Japan). Ham's F-12/DMEM and DMEM were purchased from Wako Chemicals (Tokyo, Japan). Reagents for real-time polymerase chain reaction (PCR) were purchased from Applied Biosystems (Foster, CA). HiPerFect Transfection Reagent and fluorescently labeled high-performance purity grade small interfering RNA (siRNA), used for transfection control, were purchased from QIAGEN (Valencia, CA). The QuikChange site-directed mutagenesis kit and Pfu DNA polymerase were purchased from Stratagene (La Jolla, CA). Genopure Plasmid Maxi Kit was purchased from Roche Applied Science (Penzberg, Germany). The Trizol reagent, Superscript III reverse transcriptase, E. coli DNA polymerase, RNase H, Lipofectamine Plus, pcDNA3 and pEF-1/V5-His A vectors were purchased from Invitrogen (Carlsbad, CA). A Protein Assay Kit was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA). Anti-POR (sc-25270) and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc-32233) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-aromatase (MCA2077S) antibody was purchased from AbD Serotec (Oxford, UK). The enzyme immunoassay (EIA) kits for estrone and estradiol were purchased from Cayman Chemical (Ann Arbor, MI). SiRNAs for human POR, named POR #1 (Hs_POR-2, SASI_Hs01_00216914) and POR #2 (Hs_POR-3, SASI_Hs01_00216915), were purchased from Sigma-Aldrich Japan (Tokyo, Japan). pQCXIP retroviral vector kit was purchased from Clontech Laboratories (Palo Alto, CA).

Microarray analysis

UE7T-13 MSCs [17], transduced or untransduced with SF-1 by retrovirus-mediated transfection, were cultured in DMEM supplemented with 50 mg/l gentamicin sulfate and 10% fetal bovine serum (FBS) in a humidified atmosphere containing 5% CO2 in 95% air at 37°C. Total RNA was isolated with Trizol reagent and Oligotex. cDNA was synthesized from total RNA using a Superscript III kit with T7-(dT) 24-mer primer harboring a T7 RNA polymerase promoter. The cRNA was then prepared using an Affymetrix GeneChip expression 3' amplification kit. Labeled cRNA was fragmented by incubation at 94°C for 35 min. Hybridization of cRNA for human U133 Plus 2.0 Affymetrix GeneChip and its analysis were performed as described previously [18].

Rat granulosa cell culture

Granulosa cells were obtained from immature, SLC: SD female rats (21 days old) that had received injections of 2 mg DES in 0.2 ml sesame oil once daily for 4 d. The ovaries were then excised and granulosa cells were released by puncturing the follicles with a 26-gauge needle. Animals were treated according to NIH guidelines and the experiments were approved by the animal experiment committee of the University of Fukui. Granulosa cells were washed and collected by brief centrifugation, and cell viability was determined by trypan blue exclusion. The granulosa cells were then cultured in Ham's F-12/DMEM supplemented with 50 mg/l gentamicin sulfate and 0.1% bovine serum albumin on collagen-coated plates in a humidified atmosphere containing 5% CO2 in 95% air at 37°C [19].

Hormone treatments and analysis of gene expression

Granulosa cells (5 × 106 cells) were cultured in 60-mm dishes in 5 ml medium. Ovine FSH (30 ng/ml) was added to the medium after 24 h of cell culture. The cultures were stopped at various time intervals. For the in vivo study, 21-day-old rats were primed with 30 IU eCG. After 48 h, the rats were primed with 30 IU hCG and ovaries were removed at various time intervals. KGN cells (kindly gifted by Dr. Toshihiko Yanase, Kyushu University, Fukuoka, Japan) were cultured in 60-mm dishes containing 7.5 × 106 cells in 5 ml medium and 8-Br-cAMP (final concentration 1 mM) was added to the medium 24 h after plating. The cultures were stopped at various time intervals. Total RNA was extracted from the cultured cells using Trizol reagent. Reverse transcription-PCR (RT-PCR) was performed as described previously [20]. The reaction mixture was subjected to electrophoresis in a 1.5% agarose gel, and the resulting bands were visualized by staining with ethidium bromide. The primer pairs used were: forward primer, 5'-caccacacctgtcatcatgg-3' (nucleotides 1612–1631) and reverse primer, 5'-tgaggtcggcagaagttagg-3' (nucleotides 2115–2134), for rat POR, product size: 523 bp (NM_031576); forward primer, 5'-ctggacgaaagttctattg-3' (nucleotides 679–698) and reverse primer 5'-gaagcaacatgacgtacaga-3' (nucleotides 1000–1019), for Cyp19, product size: 341 bp (NM_017085); and forward primer, 5'-ggacttctacgactggctgcagg-3' (nucleotides 541–563) and reverse primer, 5'-tcttgttggactcctcatccagg-3' (nucleotides 1141–1163), for hPOR, product size: 623 bp (NM_000941). The primer pairs for CYP19 (NM_000103), GAPDH (NM_002046), and beta-actin (NM_001101.3) have been described previously [16]. Real-time PCR was performed as described by Rutledge and Cote [21]. The primer pairs used were: forward primer, 5'-ggagacgctgctgtactacg-3' (nucleotides 1765–1784) and reverse primer, 5'-gctggacgtagaccttgtgg-3' (nucleotides 1891–1912), for human POR, product size 146 bp; forward primer, 5'-ggacttcgagcaagagatgg-3' (nucleotides 747–766) and reverse primer, 5'-aaggaaggctggaagagtgc-3' (nucleotides 862–881), for human beta-actin, product size 135 bp; forward primer, 5'-gatgacgggaacttggaaga-3' (nucleotides 662–681) and reverse primer, 5'-agctcatactggcgaatgct-3' (nucleotides 761–780), for rat POR, product size 119 bp; forward primer, 5'-tcctcagcagagaaactggaaga-3' (nucleotides 857–879) and reverse primer, 5'-cgtacagagtgacggacatggt-3', (nucleotides 986–1007) for cyp19, product size 151 bp; and forward primer, 5'-ggcgacctggaagtccaact-3' (nucleotides 47–66) and reverse primer, 5'-ggatctgctgcatctgcttg-3' (nucleotides 140–159), for rat 36B4, product size: 113 bp (NM_022402).

Western blot analysis

In order to determine protein expression levels, granulosa, KGN, and COS-7 cells (purchased from American type culture collection) were washed twice in ice-cold phosphate-buffered saline and lysed in RIPA buffer (50 mM Tris-HCl (pH 8.0) containing 1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholate, and 1 mM phenylmethylsulfonyl fluoride). The cell debris was removed by centrifugation at 15,000 × g at 4°C for 15 min, and supernatants were used as cell lysates. Proteins were quantified using a Bio-Rad Protein Assay kit. Equal amounts of protein (30 μg) were resolved by SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes. Western blot analysis of POR, CYP19, and GAPDH was performed with antisera directed against POR (raised against amino acids 1–300 of human POR), CYP19 (synthetic peptide corresponding to amino acids 376–390 of human CYP19), and GAPDH, respectively. All antibodies were capable of reacting with both human and rat antigens, respectively. Western blot analysis of POR, aromatase, and GAPDH was performed with antisera directed against POR, CYP19, and GAPDH, respectively. Enhanced chemiluminescence western blot reagents (Amersham Pharmacia Biotech, Arlington Heights, IL) were used for detection.

Plasmid constructs

Entire coding regions of human and rat POR were generated by RT-PCR using cDNA from UE7T-13 cells stably transfected with SF-1, and granulosa cells, respectively. The coding regions were then subcloned into the expression vector, pcDNA3. Human CYP19 was generated by RT-PCR using cDNA from KGN cells stimulated with 8-Br-cAMP for 12 h, and subcloned into pEF-1. Primer pairs used were: 5'-gagaGAATTCgccaccATGGATTACAAGGATGACGACGATAAGggagactcccacgtgga-3' and 5'-gagaCTCGAGctagctccacacgtccaggg-3', for human POR; 5'-gagaGAATTCgccaccATGGATTACAAGGATGACGACGATAAGggggactctcacgaagac-3' and 5'-gagaCTCGAGctagctccacacatctagtga-3', for rat POR; and 5'-gagaGATATCgccaccATGGATTACAAGGATGACGACGATAAGgttttggaaatgctgaac-3' and 5'-gagaGCGGCCGCctagtgttccagacacctgtc-3', for human CYP19. In order to obtain mutant human PORs (R457H and V492E), site-directed mutagenesis of the human POR was performed using the QuikChange Site-Directed Mutagenesis Kit. Primer pairs used were: 5'-gccgcgcctgcaggcccActactactccatcgcct-3' and 5'-aggcgatggagtagtagTgggcctgcaggcgcggc-3', for R457H; and 5'-ccgcatcaacaagggcgAggccaccaactggctgc-3' and 5'-gcagccagttggtggccTcgcccttgttgatgcgg-3', for V492E.

Transfection

COS-7 cells were cultured in DMEM supplemented with antibiotics and 10% FBS in a humidified atmosphere containing 5% CO2 and 95% air at 37°C. DNA transfections were carried out using Lipofectamine Plus reagent. All plasmids used for transfections were prepared using a Genopure Plasmid Maxi Kit. Cells (4 × 105) were cultured in 60-mm dishes in 5 ml medium on the day before transfection. Three hours after co-transfection of human aromatase (1 μg/well) and rat POR (20, 50, or 100 ng/well) or pcDNA3, medium was changed to growth medium. After 48 h, the growth medium was changed to medium containing androstenedione (final concentration 10-5 M). Culture medium was collected at various time points in order to observe the conversion of androstenedione to estrone.

EIA

The levels of estrone in the media were measured using an EIA assay kit (Cayman) according to the manufacturer's instructions. Briefly, 50 μl of diluted medium (1:1000), estrone tracer, and antiserum were added to each well. They were incubated at room temperature for 2 h and developed with Ellman's reagent solution. The developed plates were measured using a plate reader at 405 nm.

SiRNA transfection

KGN cells were cultured in DMEM/Ham's F12 supplemented with antibiotics and 10% FBS in a humidified atmosphere containing 5% CO2 and 95% air at 37°C. Knockdown of endogenous POR was carried out using siRNAs and HiPerFect reagent. Twenty-four hours after transfection, the culture medium was changed to DMEM/Ham's F12 supplemented with antibiotics and 10% FBS containing 1 mM 8-Br-cAMP and 10 μM androstenedione. Cells and medium were collected 48 h after transfection. SiRNAs for POR were POR #1 (sense: 5' GCACAUCUGUGCGGUGGUUTT, anti sense: 5' AACCACCGCACAGAUGUGCTT) and POR #2 (sense: 5' CCAACUGGCUGCGGGCCAATT, anti sense: UUGGCCCGCAGCCAGUUGGTT). They were targeted to the region approximately 1496 and 1568 nucleotides downstream from the beginning of the human POR (Ref seq NM_000941), respectively.

Statistics

Data from each experiment were analyzed using the Student's t test. P < 0.01 was considered statistically significant.

Results

Changes in gene expression in human MSCs during differentiation into steroidogenic cells

In previous studies, we converted MSCs into steroidogenic cell-lineages such as Leydig cells and adrenocortical cells by expression of SF-1 and treatment with cAMP [16]. DNA microarray analysis was performed using control and SF-1-transduced human MSCs in order to examine alterations of gene expression. Using more than 22,000 probe sets (18,400 transcripts and variants, including 14,500 well-characterized human genes), a number of differences in gene expression levels between control cells and UE7T-13 cells stably expressing SF-1 were detected: expression levels of about 1,700 genes, including POR, were found to be increased more than 5-fold in SF-1- transduced cells (representative data from two independent experiments are shown in Table 1). Gene expression of StAR [22], CYP11A1 [23], HSD3B2 [24], CYP19 [3], and CYP17A1 [25], whose transcriptions are known to be regulated by SF-1, were induced. Consistent with the results of DNA microarray, RT-PCR and real-time PCR analysis showed that POR mRNA was markedly increased more than 20-fold in UE7T-13 cells transduced with SF-1. It was further induced by the addition of 8-Br-cAMP, and reached to about 31-fold (Fig. 1A and 1B). These results indicate that, concomitant with microsomal P450 genes, the POR gene was induced during the differentiation of MSCs into steroidogenic cells, and suggest that its up-regulation may contribute to the development of the steroidogenic phenotype.
Table 1

Subset of genes induced by SF-1 in UE7T-13 human mesenchymal stem cells.

Affymetrix ID

Ratio

Accession no.

Gene Symbol

211506_s_at

488.85

AF043337

IL8

201262_s_at

463.31

BC002416

BGN

204309_at

362.16

NM_000781

CYP11A1

202411_at

274.98

NM_005532

IFI27

206294_at

225.3

NM_000198

HSD3B2

202036_s_at

160.06

AF017987

SFRP1

204548_at

153.41

NM_000349

STAR

220187_at

144.86

NM_024636

STEAP4

205498_at

96.03

NM_000163

GHR

202037_s_at

94.77

AF017987

SFRP1

203680_at

40.13

NM_002736

PRKAR2B

203632_s_at

40.06

NM_016235

GPRC5B

203475_at

32.4

NM_000103

CYP19A1

204415_at

31.5

NM_022873

IFI6

203903_s_at

24.23

NM_014799

HEPH

201010_s_at

20.95

NM_006472

TXNIP

213006_at

20.92

AV655640

CEBPD

201009_s_at

18.38

NM_006472

TXNIP

205027_s_at

17.9

NM_005204

MAP3K8

205635_at

15.66

NM_003947

KALRN

205502_at

14.89

NM_000102

CYP17A1

201981_at

14.76

AA148534

PAPPA

201416_at

14.15

NM_003107

SOX4

205302_at

13.77

NM_000596

IGFBP1

215233_at

11.12

AA351360

PTDSR

216117_at

10.42

AK025114

EXOSC2

203148_s_at

10.34

NM_014788

TRIM14

205404_at

8.66

NM_005525

HSD11B1

209540_at

8.52

M29644

IGF1

205676_at

8.51

NM_000785

CYP27B1

207135_at

8.41

NM_000621

HTR2A

210002_at

8.36

D87811

GATA6

204135_at

8.31

NM_014890

DOC1

208928_at

8.18

AF258341

POR

212095_s_at

7.41

BE552421

MTUS1

216248_s_at

6.24

S77154

NR4A2

206645_s_at

5.29

NM_000475

NR0B1

Figure 1

Induction of POR mRNA in human MSCs. A: RT-PCR analysis of POR mRNA in UE7T-13 cells transduced with SF-1 or pQCXIP (control) virus and cultured with or without 8-Br-cAMP for 2 d. B: Results of real-time PCR are also shown. Data are the mean ± SEM values of duplicate experiments.

Induction of POR expression by gonadotropins in the ovary

In order to evaluate the relevance of above hypothesis, we examined the expression of POR in the ovary and in granulosa cells, an organ and cells that are well known to be involved in steroidogenesis or in the differentiation into steroidogenic by gonadotropins. Ovarian POR mRNA was detected at relatively low levels before gonadotropin treatment. It was induced after 48 h of eCG treatment, and was further increased within 2 h of the following hCG treatment (Fig. 2A and 2B). Its expression then fell substantially at 8 h, and continued to decline thereafter. The pattern of POR expression induced by eCG and hCG was similar to that of Cyp19 expression.
Figure 2

Time-dependent changes in POR and aromatase mRNA expression in immature rat ovaries treated with eCG and hCG. A: Expression of each mRNA was examined by RT-PCR. Immature rat ovaries were primed with 30 IU eCG for 48 h, followed with treatment with 30 IU hCG for the indicated times. B: Results of real-time PCR are also shown. Data are the mean ± SEM values of at least three independent experiments. *, P < 0.01.

POR mRNA and proteins were strongly induced by FSH in granulosa cells after 3–6 h. They fell temporarily at 12 h, and then increased again from 24–48 h (Fig. 3A, B and 3C). Cyp19 mRNA and protein were barely detectable before FSH treatment. They were strongly induced by FSH, and followed a similar pattern to that of POR, although Cyp19 levels responded more quickly than POR levels. Consistent with the results from MSCs, POR was induced in the ovary and granulosa cells when they were stimulated to differentiate into steroidogenic cells by gonadotropins. Induction of Cyp19 protein by FSH causes ovarian estrogen synthesis and follicle maturation [26]. These observations suggest that FSH-induced up-regulation of POR expression, as well as that of Cyp19, could enhance estrogen synthesis in granulosa cells.
Figure 3

Regulation of POR and aromatase mRNA and protein levels by FSH. Granulosa cells isolated from immature DES-primed rats were cultured and treated with FSH (30 ng/ml) for the indicated times, and the total RNA or protein was extracted. A: RT-PCR was performed with the specific primer sets for POR, aromatase, and GAPDH. B: Results of real-time PCR are also shown. Data are the mean ± SEM values of at least three independent experiments. *, P < 0.01. C: Western blot analysis was performed with antibodies to POR, aromatase, and GAPDH, using the same lysates.

Effects of POR expression on estrogen synthesis

In order to determine if estrogen synthesis was affected by the level of POR expression when aromatase expression remained constant, POR and aromatase expression vectors were transiently co-transfected into COS-7 cells that expressed an undetectable level of aromatase protein (identified by Western blotting) and low levels of POR expression (Fig. 4A and 4B). In order to investigate aromatase enzyme activity, we measured the conversion of androstenedione to estrone in the culture medium. Estrone levels were low and were unaffected by co-transfection with both control vectors, or with the POR expression vector alone. However, time-dependent accumulation of estrone occurred when aromatase was expressed, and estrone levels were further increased by co-transfection with the POR expression vector. Co-transfection with the aromatase expression vector and 100 ng of the POR expression vector resulted in a 6-fold increase in the amount of estrone converted in 6 h, compared with the aromatase vector alone (Fig. 4A and 4B). These results suggest that estrogen synthesis is up-regulated by increasing levels of POR expression, even when aromatase expression is constant.
Figure 4

Production of estrone by co-transfection of wild-type or mutant POR and aromatase expression vectors in COS-7 cells. A and B: Amounts of estrone in the culture medium were detected by EIA at the indicated times and for the indicated contents of POR expression vector, with or without aromatase expression vector. The protein expression of POR, aromatase, and GAPDH after transfection with these amounts of vectors was detected by western blot analysis. C and D: COS-7 cells were transfected with wild-type POR or R457H or V492E mutant expression vectors (20 ng/well) with aromatase expression vector, at the indicated times. Data are means and SEM values (B) or SD values (D) of at least three assays, respectively.

We then examined the effects of the expression of mutant POR genes on estrone production. It has been reported that aromatase activity was completely lost when the R457H or V492E POR mutant proteins were expressed instead of the wild-type protein [27]. In COS-7 cells co-transfected with R457H or V492E mutant POR and aromatase expression vectors, the amount of estrone was reduced to 25% compared to co-transfection with wild-type POR and aromatase. These estrone levels were similar to those seen when aromatase was expressed alone (Fig. 4C and 4D). These results suggest that estrogen synthesis is dependent not only on the expression levels of aromatase protein, but also on the expression levels of POR protein.

Effects of knockdown of endogenous POR protein on estrogen production

We investigated the effects of knockdown of endogenous POR by siRNA in granulosa cell-derived KGN cells. Androstenedione and 8-Br-cAMP were added to the culture medium 24 h after transfection with 10 nM siRNA and the amount of estrone in the medium was measured after 48 h. In contrast to the rat granulosa cells, POR expression was relatively high in KGN cells and was not greatly changed by 8-Br-cAMP. Aromatase expression, however, was induced by 8-Br-cAMP, as in rat granulosa cells treated with FSH (Fig. 5A). POR siRNA caused a reduction in the amount of estrone to about 70% of that in cells transfected with a scrambled control siRNA (Fig. 5C). No estrone was detected in the absence of 8-Br-cAMP.
Figure 5

Effect of POR knockdown on estrone production and cAMP response of POR and aromatase genes in KGN cells. After transfection with the indicated siRNAs, the culture medium was replaced with that containing 1 mM 8-Br-cAMP and 10 μM androstenedione, and the amount of estrone in the culture medium was detected by EIA 48 h later (B and C). Data are means and SEM values of at least three assays. *, Significant difference in estrone production between KGN cells and KGN cells transfected siRNA for POR#1 or #2 (P < 0.01). The protein expression under these culture conditions at the indicated times is also shown (A and B).

Discussion

In our previous study, we reported that stable transfection of MSCs with SF-1, followed by treatment with cAMP, led to their conversion into steroidogenic cells [16]. These cells offer a possible clinical source of stem cells for the treatment of diseases of steroidogenic organs, and represent a powerful tool for studying the differentiation of the steroidogenic lineage [16, 2830]. In this study, using DNA microarray, RT-PCR, and real-time PCR analysis, we observed that POR mRNA was induced during the differentiation of hMSCs into steroidogenic cells. We also demonstrated that the expression of the POR mRNA and protein were up-regulated by FSH during the differentiation of rat granulosa cells into steroidogenic cells. Similar phenomena have been observed in adrenocortical cell lines stimulated with adrenocorticotropic hormone (ACTH) or cAMP [31, 32]. These results suggest that POR expression in steroidogenic cells is regulated by the pituitary hormone/cAMP pathway. In contrast, it has been reported that POR gene expression in hepatic cells and other organs was not changed by any stimuli, including cAMP, and in support of these observations, the promoter region of the POR gene supported constitutively high luciferase activity that was unaffected by any stimuli [3336]. These results suggest that regulation of POR gene expression differs between steroidogenic and non-steroidogenic cells. Although the reasons for this difference remain unclear, the expression of SF-1 in steroidogenic cells may explain this phenomenon. SF-1 is expressed in steroidogenic cells such as adrenocortical cells, testicular Leydig cells, ovarian theca and granulosa cells, and regulates steroidogenic genes that encode cytochrome P450scc, StAR and CYP19, by binding to cAMP-response sequences [3, 22, 23]. Our results from MSCs indicate that the POR gene could represent a new target for SF-1 in steroidogenic cells. It is therefore conceivable that the expression of POR is regulated by the pituitary hormone/cAMP pathway. Such regulations may also cause similar fluctuations in POR and CYP19 expression in the ovary and in granulosa cells. However, CYP19 mRNA was induced more rapidly than POR mRNA, because the CYP19 gene is regulated by CREB, as well as by SF-1 [3]. On the other hand, our preliminary study indicated that CREB was not involved in the induction of POR mRNA in granulosa cells by FSH (data not shown). The POR gene spans more than 70 kb, including an untranslated first exon residing about 38.8 kb upstream of the coding region [4]. Further studies are needed to understand the mechanisms regulating POR gene expression.

Based on our observations in rat ovary and in granulosa cells stimulated by gonadotropins, it is likely that increasing POR expression induced by gonadotropins further up-regulates aromatase activity, and that estrogen production is regulated not only by aromatase expression, but also by POR. This proposition is supported by the augmentation of aromatase activity coincident with increasing POR expression in COS-7 cells, despite a constant expression of aromatase. Hall and his colleagues, using purified enzymes, also reported that the activity of CYP17 was increased by the addition of POR protein in a dose-dependent manner, resulting in increased androgen production [37]. Because almost all steroidogenic enzymes are up-regulated by the pituitary hormone/cAMP pathway, our model should be applicable to other microsomal steroidogenic P450s, such as CYP17 and CYP21. In support of this hypothesis, CYP17 expression was markedly increased, together with POR, in SF-1-transduced MSCs. Similarly, the expression of ferredoxin, which is a member of the electron transport chain in mitochondria and regulates pregnenolone production by P450scc, is known to be increased by pituitary hormones and cAMP [3840]. Therefore, it is possible that, in addition to steroidogenic enzyme expression, up-regulation of electron transporter expression plays a vital role in steroid hormone production by gonadotropins and ACTH. This mechanism should be conserved between mitochondrial and microsomal steroidogenesis.

In COS-7 cells, a low level of estrone was detected in the culture medium in the absence of transfection of CYP19, even though aromatase proteins were not detected by western blotting. COS cells (COS-1 and COS-7) have often been used for measuring aromatase activity by ectopic expression of the CYP19 gene, and low aromatase activities have been reported under non-transfected conditions [4144]. It is thus conceivable that aromatase proteins are expressed at very low levels in this cell line. It has been reported that the R457H and V492E POR mutations are associated with loss of P450 enzyme activities, because these mutations in the FAD domain hamper the ability of POR to transfer electrons to its FMN group, which ultimately provides electrons to P450 enzymes [27]. When these mutants were expressed concomitantly with aromatase in COS-7 cells, estrone production was similar to that seen with aromatase alone. This result indicates that the augmentation of aromatase activity by POR is not a side effect of overexpression of POR, but is due to the increased electron supply resulting from increased POR expression in COS-7 cells.

FSH, forskolin, and cAMP have been reported to cause increases in aromatase activity in KGN cells (a human ovarian granulosa-like tumor cell line), as well as in rat granulosa cells [45, 46]. In contrast, POR expression in KGN cells was little changed by 8-Br-cAMP treatment, and was much higher than in primary cultures of rat granulosa cells. In addition, it has been reported that the lower amount of POR protein, compared with the amount of P450 protein, was still sufficient to carry out all metabolic reactions [47]. Hence, the amount of POR expression after inhibition by siRNA, still seemed to be sufficient to activate aromatase induced by 8-Br-cAMP. Therefore, estrone production should not be greatly reduced by POR siRNA. POR is involved not only in steroidogenesis, but also in drug and xenobiotic metabolism, and in tumorigenesis [48, 49]. It is likely that the hormone-responsiveness of the POR gene is lost during immortalization of KGN cells. However, induction of POR in granulosa cells may play a more significant role in estrogen production, because the amount of POR protein in these cells is limited. In granulosa cells, POR and aromatase expression are regulated by gonadotropins, which in turn may be responsible for coordinated regulation of steroid hormone production at each stage of follicular growth.

In this study, we have demonstrated that estrogen production was caused not only by aromatase expression, but also through the promotion of aromatase activity by FSH-induced POR expression in ovarian granulosa cells. POR knockout mice are embryonically lethal, but POR heterozygous knockout mice are fertile, and do not have ambiguous genitalia [50]. Our study suggests that a comparison of ovarian function and morphology between POR heterozygous knockout mice and aromatase knockout mice [51] could provide further useful information. In addition, POR might be involved in the differentiation of these steroidogenic organs through activation of microsomal P450 enzymes.

Declarations

Acknowledgements

We are grateful to Dr. T. Yanase for providing the KGN cells. We also thank Ms. Y. Inoue and K. Matsuura for technical assistance. This work was supported by grants from the Research and Education Program for Life Science, University of Fukui, Ministry of Education, Science, Sports and Culture of Japan, from the Smoking Research Foundation, 21st Century COE Program (Medical Science) and a Yukitoshi Maeda Foundation scholarship.

Authors’ Affiliations

(1)
Department of Biochemistry, Faculty of Medical Sciences, University of Fukui
(2)
National Cardiovascular Research Center
(3)
National Research Institute for Child Health and Development

References

  1. Richards JS: Maturation of ovarian follicles: actions and interactions of pituitary and ovarian hormones on follicular cell differentiation. Physiol Rev. 1980, 60: 51-89.PubMedGoogle Scholar
  2. Hirshfield AN: Development of follicles in the mammalian ovary. Int Rev Cytol. 1991, 124: 43-101.View ArticlePubMedGoogle Scholar
  3. Carlone DL, Richards JS: Functional interactions, phosphorylation, and levels of 3',5'-cyclic adenosine monophosphate-regulatory element binding protein and steroidogenic factor-1 mediate hormone-regulated and constitutive expression of aromatase in gonadal cells. Mol Endocrinol. 1997, 11: 292-304.PubMedGoogle Scholar
  4. Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL: Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2007, 92: 2318-2322.View ArticlePubMedGoogle Scholar
  5. Haniu M, McManus ME, Birkett DJ, Lee TD, Shively JE: Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. Biochemistry. 1989, 28: 8639-8645.View ArticlePubMedGoogle Scholar
  6. Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V: P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann N Y Acad Sci. 2005, 1061: 100-108.View ArticlePubMedGoogle Scholar
  7. Lu AY, Junk KW, Coon MJ: Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components. J Biol chem. 1969, 244: 3714-3721.PubMedGoogle Scholar
  8. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, Miller WL: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet. 2004, 36: 228-230.View ArticlePubMedGoogle Scholar
  9. Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006, 59: 276-280.View ArticlePubMedGoogle Scholar
  10. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, Stewart PM, Shackleton CH: Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004, 363: 2128-2135.View ArticlePubMedGoogle Scholar
  11. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, Matsuo N, Sato S, Homma K, Nishimura G, Hasegawa T, Ogata T: Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab. 2005, 90: 414-426.View ArticlePubMedGoogle Scholar
  12. Miller WL: P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab. 2004, 15: 311-315.View ArticlePubMedGoogle Scholar
  13. Friedenstein AJ, Gorskaja JF, Kulagina NN: Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976, 4: 267-274.PubMedGoogle Scholar
  14. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997, 276: 71-74.View ArticlePubMedGoogle Scholar
  15. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F: Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 1998, 279: 1528-1530.View ArticlePubMedGoogle Scholar
  16. Yazawa T, Mizutani T, Yamada K, Kawata H, Sekiguchi T, Yoshino M, Kajitani T, Shou Z, Umezawa A, Miyamoto K: Differentiation of adult stem cells derived from bone marrow stroma into Leydig or adrenocortical cells. Endocrinology. 2006, 147: 4104-4111.View ArticlePubMedGoogle Scholar
  17. Mori T, Kiyono T, Imabayashi H, Takeda Y, Tsuchiya K, Miyoshi S, Makino H, Matsumoto K, Saito H, Ogawa S, Sakamoto M, Hata J, Umezawa A: Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. Mol Cell Biol. 2005, 25: 5183-5195.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Abe Y, Sinozaki H, Takagi T, Minegishi T, Kokame K, Kangawa K, Uesaka M, Miyamoto K: Identification of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible genes in human amniotic epithelial cells. Reprod Biol Endocrinol. 2006, 4: 27-PubMed CentralView ArticlePubMedGoogle Scholar
  19. Minegishi T, Tano M, Nakamura K, Nakamura M, Igarashi S, Ito I, Shinozaki H, Karino S, Ibuki Y, Miyamoto K: Regulation of follicle-stimulating hormone receptor. Horm Res. 1996, 46: 37-44.View ArticlePubMedGoogle Scholar
  20. Mizutani T, Yamada K, Yazawa T, Okada T, Minegishi T, Miyamoto K: Cloning and characterization of gonadotropin-inducible ovarian transcription factors (GIOT1 and -2) that are novel members of the (Cys)(2)-(His)(2)-type zinc finger protein family. Mol Endocrinol. 2001, 15: 1693-1705.View ArticlePubMedGoogle Scholar
  21. Rutledge RG, Cote C: Mathematics of quantitative kinetic PCR and the application of standard curves. Nucleic Acids Res. 2003, 31: e93-PubMed CentralView ArticlePubMedGoogle Scholar
  22. Sandhoff TW, Hales DB, Hales KH, McLean MP: Transcriptional regulation of the rat steroidogenic acute regulatory protein gene by steroidogenic factor 1. Endocrinology. 1998, 139: 4820-4831.PubMedGoogle Scholar
  23. Clemens JW, Lala DS, Parker KL, Richards JS: Steroidogenic factor-1 binding and transcriptional activity of the cholesterol side-chain cleavage promoter in rat granulosa cells. Endocrinology. 1994, 134: 1499-1508.PubMedGoogle Scholar
  24. Leers-Sucheta S, Morohashi K, Mason JI, Melner MH: Synergistic activation of the human type II 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester. J Biol Chem. 1997, 272: 7960-7967.View ArticlePubMedGoogle Scholar
  25. Zhang P, Mellon SH: The orphan nuclear receptor steroidogenic factor-1 regulates the cyclic adenosine 3',5'-monophosphate-mediated transcriptional activation of rat cytochrome P450c17 (17 α-hydroxylase/c17–20 lyase). Mol Endocrinol. 1996, 10: 147-158.PubMedGoogle Scholar
  26. Hickey GJ, Chen S, Besman MJ, Shively JE, Hall PF, Gaddy-Kurten D, Richards JS: Hormonal regulation, tissue distribution, content of aromatase cytochrome P450 messenger ribonucleic acid, enzyme in rat ovarian follicles, corpora lutea: relationship to estradiol biosynthesis. Endocrinology. 1988, 122 (4): l426-l436.View ArticleGoogle Scholar
  27. Pandey AV, Kempná P, Hofer G, Mullis PE, Flück CE: Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol. 2007, 21: 2579-2595.View ArticlePubMedGoogle Scholar
  28. Yazawa T, Uesaka M, Inaoka Y, Mizutani T, Sekiguchi T, Kajitani T, Kitano T, Umezawa A, Miyamoto K: Cyp11b1 is induced in the murine gonad by luteinizing hormone/human chorionic gonadotropin and involved in the production of 11-ketotestosterone, a major fish androgen: conservation and evolution of the androgen metabolic pathway. Endocrinology. 2008, 149: 1786-1792.View ArticlePubMedGoogle Scholar
  29. Gondo S, Yanase T, Okabe T, Tanaka T, Morinaga H, Nomura M, Goto K, Nawata H: SF-1/Ad4BP transforms primary long-term cultured bone marrow cells into ACTH-responsive steroidogenic cells. Genes Cells. 2004, 9: 1239-1247.View ArticlePubMedGoogle Scholar
  30. Tanaka T, Gondo S, Okabe T, Ohe K, Shirohzu H, Morinaga H, Nomura M, Tani K, Takayanagi R, Nawata H, Yanase T: Steroidogenic factor 1/adrenal 4 binding protein transforms human bone marrow mesenchymal cells into steroidogenic cells. J Mol Endocrinol. 2007, 39: 343-350.View ArticlePubMedGoogle Scholar
  31. Schimmer BP, Cordova M, Cheng H, Tsao A, Goryachev AB, Schimmer AD, Morris Q: Global profiles of gene expression induced by adrenocorticotropin in Y1 mouse adrenal cells. Endocrinology. 2006, 147: 2357-2367.View ArticlePubMedGoogle Scholar
  32. Tee MK, Dong Q, Miller WL: Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis. Endocrinology. 2008, 149: 2667-2677.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Simmons DL, Kasper CB: Quantitation of mRNAs specific for the mixed-function oxidase system in rat liver and extrahepatic tissues during development. Arch Biochem Biophys. 1989, 271: 10-20.View ArticlePubMedGoogle Scholar
  34. O'Leary KA, Beck TW, Kasper CB: NADPH cytochrome P-450 oxidoreductase gene: identification and characterization of the promoter region. Arch Biochem Biophys. 1994, 310: 452-459.View ArticlePubMedGoogle Scholar
  35. O'Leary KA, McQuiddy P, Kasper CB: Transcriptional regulation of the TATA-less NADPH cytochrome P-450 oxidoreductase gene. Arch Biochem Biophys. 1996, 330: 271-280.View ArticlePubMedGoogle Scholar
  36. O'Leary KA, Kasper CB: Molecular basis for cell-specific regulation of the NADPH-cytochrome P450 oxidoreductase gene. Arch Biochem Biophys. 2000, 379: 97-108.View ArticlePubMedGoogle Scholar
  37. Yanagibashi K, Hall PF: Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. J Biol Chem. 1986, 261: 8429-8433.PubMedGoogle Scholar
  38. Chang CY, Huang C, Guo IC, Tsai HM, Wu DA, Chung BC: Transcription of the human ferredoxin gene through a single promoter which contains the 3', 5'-cyclic adenosine monophosphate-responsive sequence and Sp 1-binding site. Mol Endocrinol. 1992, 6: 1362-1370.PubMedGoogle Scholar
  39. Yeh JR, Huang C, Wu DA, Guo IC, Rainey WE, Chung BC: Regulation of ferredoxin gene in steroidogenic and nonsteroidogenic cells. J Steroid Biochem Mol Biol. 1995, 53: 47-51.View ArticlePubMedGoogle Scholar
  40. Black SM, Szklarz GD, Harikrishna JA, Lin D, Wolf CR, Miller WL: Regulation of proteins in the cholesterol side-chain cleavage system in JEG-3 and Y-1 cells. Endocrinology. 1993, 132: 539-545.PubMedGoogle Scholar
  41. Chang X, Kobayashi T, Senthilkumaran B, Kobayashi-Kajura H, Sudhakumari CC, Nagahama Y: Two types of aromatase with different encoding genes, tissue distribution and developmental expression in Nile tilapia (Oreochromis niloticus). Gen Comp Endocrinol. 2005, 141: 101-115.View ArticlePubMedGoogle Scholar
  42. Tong SK, Chiang EF, Hsiao PH, Chung B: Phylogeny, expression and enzyme activity of zebrafish cyp19 (P450 aromatase) genes. J Steroid Biochem Mol Biol. 2001, 79: 299-303.View ArticlePubMedGoogle Scholar
  43. Harada N, Ogawa H, Shozu M, Yamada K, Suhara K, Nishida E, Takagi Y: Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. J Biol Chem. 1992, 267: 4781-4785.PubMedGoogle Scholar
  44. McPhaul MJ, Noble JF, Simpson ER, Mendelson CR, Wilson JD: The expression of a functional cDNA encoding the chicken cytochrome P-450arom (aromatase) that catalyzes the formation of estrogen from androgen. J Biol Chem. 1988, 263: 16358-16363.PubMedGoogle Scholar
  45. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, Okabe T, Goto K, Takayanagi R, Kashimura Y, Haji M, Nawata H: Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology. 2001, 142: 437-445.View ArticlePubMedGoogle Scholar
  46. Wu Y, Ghosh S, Nishi Y, Yanase T, Nawata H, Hu Y: The orphan nuclear receptors NURR1 and NGFI-B modulate aromatase gene expression in ovarian granulosa cells: a possible mechanism for repression of aromatase expression upon luteinizing hormone surge. Endocrinology. 2005, 146: 237-246.View ArticlePubMedGoogle Scholar
  47. Reed JR, Kelley RW, Backes WL: An evaluation of methods for the reconstitution of cytochromes P450 and NADPH P450 reductase into lipid vesicles. Drug Metab Dispos. 2006, 34: 660-666.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Wang XJ, Chamberlain M, Vassieva O, Henderson CJ, Wolf CR: Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice. Biochem J. 2005, 388: 857-867.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, Waxman DJ: P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos. 2001, 29: 304-312.PubMedGoogle Scholar
  50. Shen AL, O'Leary KA, Kasper CB: Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem. 2002, 277: 6536-6541.View ArticlePubMedGoogle Scholar
  51. Fisher CR, Graves KH, Parlow AF, Simpson ER: Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA. 1998, 95: 6965-6970.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Inaoka et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement